Final Report on Real World Effectiveness of Sequential Afatinib and Osimertinib in EGFR Positive Advanced Non-small Cell Lung Cancer

被引：0
|
作者：
Jang, T. W. [1 ]
Kim, T. [2 ]
机构：
[1] Kosin Univ Gospel Hosp, Busan, South Korea
[2] Armed Forces Goyang Hosp, Goyang, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Afatinib; osimertinib; real-world effectiveness;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-27
引用
收藏
页码：S651 / S651
页数：1
相关论文
共 50 条
  • [21] Real-World Experience of First-Line Afatinib Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
    Liam, C.
    Ho, G.
    Chai, C.
    Alip, A. Bt
    Pang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S998 - S999
  • [22] Real-world experience of treatment with afatinib in advanced non-small cell lung cancer (NSCLC) in Vietnam
    Dong, H.
    Tuan, K. Nguyen
    Bui, T. T. P.
    Dong, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1590 - S1590
  • [23] Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
    Pan, Jie
    Cai, Xiaoping
    Cao, Zhuo
    Pan, Jiongwei
    Zheng, Hao
    PHARMACOLOGY, 2023, 108 (01) : 8 - 16
  • [24] REAL-WORLD EFFECTIVENESS OF OSIMERTINIB IN NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: SYSTEMATIC REVIEW AND META-ANALYSIS
    Almutairi, A.
    Alkhatib, N.
    Maghaireh, M.
    Halloush, S.
    Rashdan, O.
    Manasrah, A.
    Abraham, I
    Almaaytah, A.
    Abumansour, H.
    Saleh, M.
    Khassawaneh, A.
    VALUE IN HEALTH, 2023, 26 (06) : S188 - S188
  • [25] Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
    Paulina Bracht, Jillian Wilhelmina
    Karachaliou, Niki
    Berenguer, Jordi
    Pedraz-Valdunciel, Carlos
    Filipska, Martyna
    Codony-Servat, Carles
    Codony-Servat, Jordi
    Rosell, Rafael
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (12): : 2607 - 2614
  • [26] Recent Insights into Osimertinib Analogues against EGFR Positive Non-small Cell Lung Cancer
    Chhabra, Jatin
    Kashyap, Priyanka
    Pahwa, Rakesh
    Narang, Rakesh
    Dureja, Harish
    Lal, Sukhbir
    Verma, Sangeeta
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2023, 23 (21) : 2001 - 2026
  • [27] Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer
    Alsharedi, M.
    Bukamur, H.
    Elhamdani, A.
    DRUGS OF TODAY, 2018, 54 (06) : 369 - 379
  • [28] Osimertinib for treating Patients with EGFR Mutation-Positive non-small cell Lung Cancer
    Meinrenken, Susanne
    PNEUMOLOGIE, 2018, 72 (04): : 246 - 246
  • [29] Real-World Effectiveness of EGFR TKI First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in US
    Gautam, S.
    Herms, L.
    Bartolome, L.
    Pastel, M.
    Wilner, K.
    Fisher, M.
    Ivanova, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S618 - S619
  • [30] Multicentered Real-World Evidence of Osimertinib Treatment in EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) In Thailand
    Thamrongjirapat, T.
    Sitthideatphaiboon, P.
    Oranratnachai, S.
    Khiewngam, K.
    Maneenil, K.
    Prasongsook, N.
    Korphaisarn, K.
    Wangsubtawee, S.
    Rattanaphom, A.
    Reungwetwattana, T.
    Sriuranpong, V.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S624 - S625
12345